drug

EIK1001

1 story · latest Aug 13, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Eikon Therapeutics

Timeline

Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progress

Aug 13Quarterly updateEikon Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.